Medicus Pharma (MDCX) Projected to Post Earnings on Monday

Medicus Pharma (NASDAQ:MDCX) is expected to announce its results before the market opens on Monday, August 10th. Analysts expect Medicus Pharma to announce earnings of ($0.14) per share for the quarter.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13). On average, analysts expect Medicus Pharma to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Medicus Pharma Stock Up 1.5%

Shares of NASDAQ:MDCX opened at $0.28 on Monday. The stock has a market capitalization of $15.82 million, a P/E ratio of -0.10 and a beta of -0.05. Medicus Pharma has a 52 week low of $0.25 and a 52 week high of $3.05. The firm has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.61.

Institutional Trading of Medicus Pharma

A number of hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC bought a new stake in Medicus Pharma during the fourth quarter valued at about $2,771,000. Jane Street Group LLC acquired a new stake in Medicus Pharma in the fourth quarter worth about $92,000. HRT Financial LP purchased a new stake in shares of Medicus Pharma during the fourth quarter worth about $42,000. Wilmington Savings Fund Society FSB grew its stake in shares of Medicus Pharma by 100.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after acquiring an additional 25,622 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a report on Monday, April 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a report on Wednesday, July 8th. Alliance Global Partners initiated coverage on shares of Medicus Pharma in a research note on Tuesday, July 28th. They issued a “buy” rating on the stock. Finally, Roth Capital started coverage on shares of Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.00.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.